This acquisition enables Foster Wheeler to re-establish its position in the North American pharmaceutical market and strengthens its position relative to key US pharmaceutical companies seeking to invest in the US and globally. In addition, this acquisition will provide enhanced capabilities to existing Biokinetics clients.
Umberto della Sala, president and COO of Foster Wheeler, said: “This acquisition is part of Foster Wheeler’s overall strategy to complement organic growth in our Global Engineering & Construction business with highly targeted acquisitions. This particular transaction enables us to expand our global presence in this sector and further enhance our existing biopharmaceutical skills base.”